JAZZ Long Put Strategy
JAZZ (Jazz Pharmaceuticals plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ (Jazz Pharmaceuticals plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $14.58B, a trailing P/E of 487.62, a beta of 0.27 versus the broader market, a 52-week range of 103.6-235, average daily share volume of 1.0M, a public-listing history dating back to 2007, approximately 3K full-time employees. These structural characteristics shape how JAZZ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.27 indicates JAZZ has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 487.62 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a long put on JAZZ?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current JAZZ snapshot
As of May 15, 2026, spot at $228.38, ATM IV 32.20%, IV rank 11.60%, expected move 9.23%. The long put on JAZZ below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long put structure on JAZZ specifically: JAZZ IV at 32.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a JAZZ long put, with a market-implied 1-standard-deviation move of approximately 9.23% (roughly $21.08 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JAZZ expiries trade a higher absolute premium for lower per-day decay. Position sizing on JAZZ should anchor to the underlying notional of $228.38 per share and to the trader's directional view on JAZZ stock.
JAZZ long put setup
The JAZZ long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JAZZ near $228.38, the first option leg uses a $230.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JAZZ chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JAZZ shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $230.00 | $9.65 |
JAZZ long put risk and reward
- Net Premium / Debit
- -$965.00
- Max Profit (per contract)
- $22,034.00
- Max Loss (per contract)
- -$965.00
- Breakeven(s)
- $220.35
- Risk / Reward Ratio
- 22.833
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
JAZZ long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on JAZZ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$22,034.00 |
| $50.50 | -77.9% | +$16,984.50 |
| $101.00 | -55.8% | +$11,935.01 |
| $151.49 | -33.7% | +$6,885.51 |
| $201.99 | -11.6% | +$1,836.01 |
| $252.48 | +10.6% | -$965.00 |
| $302.98 | +32.7% | -$965.00 |
| $353.47 | +54.8% | -$965.00 |
| $403.97 | +76.9% | -$965.00 |
| $454.46 | +99.0% | -$965.00 |
When traders use long put on JAZZ
Long puts on JAZZ hedge an existing long JAZZ stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying JAZZ exposure being hedged.
JAZZ thesis for this long put
The market-implied 1-standard-deviation range for JAZZ extends from approximately $207.30 on the downside to $249.46 on the upside. A JAZZ long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long JAZZ position with one put per 100 shares held. Current JAZZ IV rank near 11.60% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JAZZ at 32.20%. As a Healthcare name, JAZZ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JAZZ-specific events.
JAZZ long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JAZZ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JAZZ alongside the broader basket even when JAZZ-specific fundamentals are unchanged. Long-premium structures like a long put on JAZZ are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current JAZZ chain quotes before placing a trade.
Frequently asked questions
- What is a long put on JAZZ?
- A long put on JAZZ is the long put strategy applied to JAZZ (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With JAZZ stock trading near $228.38, the strikes shown on this page are snapped to the nearest listed JAZZ chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JAZZ long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the JAZZ long put priced from the end-of-day chain at a 30-day expiry (ATM IV 32.20%), the computed maximum profit is $22,034.00 per contract and the computed maximum loss is -$965.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JAZZ long put?
- The breakeven for the JAZZ long put priced on this page is roughly $220.35 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JAZZ market-implied 1-standard-deviation expected move is approximately 9.23%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on JAZZ?
- Long puts on JAZZ hedge an existing long JAZZ stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying JAZZ exposure being hedged.
- How does current JAZZ implied volatility affect this long put?
- JAZZ ATM IV is at 32.20% with IV rank near 11.60%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.